GC Biopharma announced that the World Health Organization (WHO) has awarded prequalification to filling and finish plant on February 3 2023, located in Ochang, South Korea. This plant is the larger filling and finish facility based in South Korea, established in 2019. GC Biopharma installed an isolator facilities and applied a single-use system in the site, and it has automation facilities that automate the entire process from raw material warehousing to production and shipment.

GC Biopharma can produce 300 million doses annually here, enabling CMO of Drug Products (DP) for vaccines (Sterile vials and Prefilled syringe) and non-vaccine filling & finish and packaging. Based on this PQ certification, GC Biopharma has established a global-level production hub that can manufacture the products at the global standards, to this facility following a vaccine plant located in Hwa-sun, South Korea. GC Biopharma supplies a large amount of seasonal flu vaccines every year through PAHO (Pan American health Organization) and UNICEF under the WHO and has been supplying more than 50 million doses of flu vaccines even in the COVID-19 pandemic situation for the past three years.